Market News & Trends
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections From Ongoing Phase 3 Study
SCYNEXIS, Inc. recently announced the presentation of cumulative interim outcomes and all-cause mortality data in patients with refractory candidiasis treated with oral ibrexafungerp from the…
Taconic Biosciences Launches First & Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors for Improved Antibody Therapy Assessment
Taconic Biosciences has recently launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcγRs) known…
Catalent Expands Biologics Analytical Capabilities With New Laboratories at Center of Excellence in Kansas City, MO
Catalent recently announced a $12-million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, MO. The project will see…
BD, Biocorp Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs
BD (Becton, Dickinson and Company) and Biocorp recently announced they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies….
Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
Comera Life Sciences Holdings, Inc. recently announced favorable results from its recently completed SEQURUS-2 study. Together with the SEQURUS-1 study, the preclinical results showed that Comera’s…
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating Treatment of B-cell Acute Lymphoblastic Leukemia
Gracell Biotechnologies Inc. recently announced the first patient has been dosed in the Phase 2 portion of its registrational Phase 1/2 clinical trial evaluating GC007g…
Bora Pharmaceutical Makes Strategic Appointment to Strengthen Global Manufacturing Capabilities
Bora Pharmaceuticals, a full-service contract development and manufacturing organization (CDMO), recently appointed Don Liscombe as its Vice President and General Manager to lead its flagship…
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
PTC Therapeutics, Inc. recently announced enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington's disease at…
Alvotech & JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates, Bringing New Options for Patients in Specialty Care
Alvotech and the JAMP Pharma Group recently announced the companies have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech, by adding…
Jazz Pharmaceuticals & Zymeworks Announce Exclusive License Agreement
Jazz Pharmaceuticals plc and Zymeworks Inc. recently announced Jazz and Zymeworks’ subsidiary, Zymeworks BC Inc., have entered into an exclusive licensing agreement under which Jazz will acquire….
Societal CDMO Announces Signing of Multiple New CDMO Service Agreements
Societal CDMO, Inc. recently announced it has signed CDMO service agreements with two new customers. These contracts are focused on a range of analytical method, technical transfer, formulation, manufacturing and….
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Preclinical Study
Silo Pharma, Inc. recently announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD), as demonstrated in a mouse…
Aragen to Operationalize Cutting-Edge Formulation Manufacturing Facility
Aragen recently announced it will operationalize its state-of-the-art formulation manufacturing facility in the Mallapur campus, Hyderabad, India, by January 2023. The 12,000-sq-ft new facility will…
Pistoia Alliance Launches Global Community of Interest to Assess the Environmental Impact of Clinical Trials
The Pistoia Alliance recently announced the launch of the Clinical Trials Environmental Impact Community of Interest (CoI) to measure and compare the carbon footprint of centralized (traditional site-based) and decentralized clinical trials…..
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Crinetics Pharmaceuticals, Inc. recently announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating…
VBI Vaccines & Agenus Announce Collaboration to Evaluate VBI-1901 in Combination With Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
VBI Vaccines Inc. and Agenus recently announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal….
Thermo Fisher Scientific Unveils New Clinical Research Laboratory in Virginia
Thermo Fisher Scientific recently expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, VA. The new unit will…
Tavros Therapeutics & Vividion Therapeutics Announce Strategic Collaboration to Discover & Enhance Targeted Oncology Programs
Tavros Therapeutics and Vividion Therapeutics, Inc. recently announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term…..
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
BriaCell Therapeutics Corp. recently announced today it has added Mayo Clinic, Jacksonville, FL, as a clinical site in the Phase 1/2 study of BriaCell’s lead…
Syneos Health Expands Partnership With Datavant to Accelerate Delivery of New Therapies to Patients
Syneos Health recently announced an expanded partnership with Datavant, the leader in helping organizations securely connect health data. The increasing collaboration between the companies will further leverage….
